Highlighting Triglycerides, APOC3 and Cardiovascular Health – New Data presented at ESC 2026

New research highlights a close connection between elevated triglycerides, inflammation, and cardiovascular health. Our clinical data show that patients with higher fasting triglyceride levels have a more inflammatory and metabolically unhealthy profile, along with poorer cardiovascular function. Meanwhile, our Phase 1 results for RBD5044, an APOC3-targeting siRNA, demonstrate that substantial and long-lasting triglyceride reduction is accompanied by favorable changes in lipid-related proteins and inflammatory biomarkers. Together, these findings suggest that APOC3 silencing may do more than lower triglycerides. By targeting a key driver of elevated blood fats, it may also help address the underlying metabolic and inflammatory processes that contribute to cardiovascular disease. RBD5044 is currently being evaluated in global Phase 3-enabling Phase 2 clinical trials. The data was presented in its full context as posters at ESC August 28-31, 2026: “Apolipoprotein and inflammatory biomarker changes following marked triglyceride reduction with the GalNAc-conjugated APOC3 siRNA RBD5044” Link “Elevated fasting triglyceride levels are associated with adverse molecular profiles and impaired functional imaging measures in patients with suspected myocardial ischemia” Link Share on social media Facebook-f Twitter Linkedin-in

The release as fetched from its publisher. ribocure.com ↗